Navigation Links
Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
Date:10/23/2007

NUTLEY, N.J., Oct. 23 /PRNewswire/ -- Today, Roche announced positive results from a Phase I trial of R1507, a human monoclonal antibody to target IGF-1R (insulin-like growth factor receptor), in patients with solid tumors. IGF-1 is one of the most potent natural activators of the AKT and MAPK signaling pathways, which promote cell growth and cell survival. The IGF-1R pathway has also been shown to have an important role in mediating the resistance to cytotoxic drugs and EGFR/HER2-targeted agents. The results were reported during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in San Francisco.

Study Results

In the Phase I study, R1507 was administered by intravenous infusion. Nine of 34 adult patients with advanced solid tumors experienced disease stabilization. Four of the seven heavily pretreated patients with Ewing's sarcoma demonstrated clinical benefit with two of these patients achieving durable, objective partial responses.

Once a week administration of R1507 was well tolerated with very few side effects. Treatment with R1507 was not associated with the typical side-effects normally observed with cancer therapy (e.g., low blood counts, infection, hair loss, severe nausea and vomiting). The most frequent side effects observed were fatigue, anorexia and weight loss, symptoms that are commonly observed in patients with advanced cancer.

"We are very encouraged by these early results with R1507 in patients with refractory Ewing's sarcoma," said Kapil Dhingra, MD, Head, Oncology Disease Biology Area at Roche. "As a result, we have given this program a very high priority as we believe this molecule has the potential to be very beneficial in treating patients with sarcoma as well as a variety of other solid tumors."

The antibody (R1507) was initially developed under Roche's broad antibody development collaboration with Genmab, which began in 2001.

The Phase I study is being conducted at four sites in the U.S., including the University of Colorado Cancer Center (Aurora, CO), The University of Texas M.D. Anderson Cancer Center (Houston, TX), Cancer Institute of New Jersey (New Brunswick, NJ) and The Institute for Drug Development (San Antonio, TX). R1507 has also been investigated in 26 patients on a three week schedule in the Phase I study. This treatment schedule was also generally well tolerated with a side effect profile similar to the weekly schedule.

"This drug attacks the IGF pathway and may provide a new class of drugs to treat a variety of cancers, including breast, prostate, colon, melanoma, myeloma and a variety of sarcomas, which could greatly add to the way that we currently treat these patients," says Stephen Leong, M.D., assistant professor of Medical Oncology at the University of Colorado Cancer Center and lead author of the abstract.

Razelle Kurzrock, MD, investigator at the M.D. Anderson Cancer Center and the senior author of the abstract, noted that some of the responses were very impressive. For instance, one 28 year-old Ewing's sarcoma patient with large tumors unresponsive to many other treatments showed dramatic tumor shrinkage within six weeks, without side effects. "This is one of the best responses I've seen in over 20 years of oncology experience," stated Dr. Kurzrock.

Based on these initial results with R1507, Roche plans to conduct additional trials and work with a global consortium of sarcoma experts, including the Sarcoma Alliance for Research through Collaboration (SARC). "We are very excited about our collaboration with SARC, which represents a new approach to sarcoma clinical trials, and we look forward to combining our expertise with that our colleagues at SARC to expedite new sarcoma treatments," added Dhingra.

"We are excited to be partnering with Roche on the development of a new treatment against an important target, which could result in a potential breakthrough treatment for sarcoma as well as other cancers," said Laurence Baker, DO, professor of Medicine and Pharmacology at the University of Michigan and the Executive Director, SARC. "With Roche's considerable expertise in oncology and SARC's vast network of physicians and institutions, we look forward to determining the potential of R1507 in this important disease area."

About Ewing's Sarcoma

The Ewing's family of tumors (EFT) includes primary tumors of bone (classic Ewing's sarcoma, primitive neuroectodermal tumor, and Askin tumor) and extraosseous primary tumors {National Cancer Institute}. Studies using immunohistochemical markers, cytogenetics, molecular genetics, and tissue culture indicate that these tumors are all derived from the same primordial stem cell. EFTs account for 4 percent of childhood and adolescent malignancies. The estimated incidence (US) is approximately 300 new cases per year. The median age for patients with EFT is 15 years and more than 50 percent of patients are adolescents. There is a slight male predominance and the lower limbs are affected in 40 percent of the patients.

Approximately 20 to 30 percent of the patients with ETB have overt metastases at the time of diagnosis. However, outcomes for patients with metastatic disease have improved little during the last 20 years. Approximately 25-30 percent survival could be achieved with current therapies for patients who present with metastatic disease at initial diagnosis.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News and one of the Top 20 Employers (Science magazine). In 2006, Roche was ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or http://www.roche.us.

About SARC

The purpose of the Sarcoma Alliance for Research through Collaboration (SARC) is to engage all appropriate and necessary resources to cure and prevent sarcoma. SARC brings together expert sarcoma researchers and clinicians from 29 centers of excellence in the United States. SARC by the charter, promotes international collaboration in sarcoma clinical trials through is association with European sarcoma experts. SARC is unique as a clinical trial organization in that its trials at the inception include pediatric and medical patients with sarcoma, because sarcomas affect people of all ages. SARC is a 501c3, non-profit organization that is headquartered in Ann Arbor, Michigan.


'/>"/>
SOURCE Hoffmann-La Roche Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... 2016  Eli Lilly and Company (NYSE: ... 3 EXPEDITION3 trial at the 9 th Clinical ... solanezumab did not meet the primary endpoint in the ... people with mild dementia due to Alzheimer,s disease (AD), ... for the treatment of mild dementia due to AD. ...
Breaking Medicine Technology:
(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...
(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... DrugDev ... the announcement that it is one of the early adopters completing EU-U.S. Privacy Shield ... is designed to provide companies on both sides of the Atlantic with a mechanism ...
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
Breaking Medicine News(10 mins):